PART I Overview We are a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. We leverage our teams deep expertise in chemistry and structure-based drug design to develop innovative small molecules that are designed with the aim to overcome the limitations of existing therapies for clinically proven kinase targets. Limitations faced by currently available kinase inhibitors can include (i) kinase resistance, or the emergence of new mu...
Q2 FY2026 — expected 2026-09-16
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001193125-26-073317 | EDGAR | 113K words |
| 2025-02-27 | 2024-12-31 | 0000950170-25-028328 | EDGAR | — |
| 2024-02-27 | 2023-12-31 | 0000950170-24-020607 | EDGAR | — |
| 2023-03-16 | 2022-12-31 | 0000950170-23-008284 | EDGAR | — |
| 2022-03-29 | 2021-12-31 | 0001193125-22-087401 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-10-30 | 2025-09-30 | 0001193125-25-257357 | EDGAR | 75K words |
| 2025-08-07 | 2025-06-30 | 0000950170-25-104532 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0000950170-25-066401 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0000950170-24-124518 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0000950170-24-093285 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0000950170-24-056232 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0000950170-23-063341 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0000950170-23-040937 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0000950170-23-020807 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0000950170-22-024138 | EDGAR | — |
| 2022-08-10 | 2022-06-30 | 0001193125-22-216780 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0001193125-22-148022 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-07-15 | 0001193125-26-304126 | EDGAR | — |
| 2026-02-26 | 0001193125-26-073304 | EDGAR | 2K words |
| 2026-01-14 | 0001193125-26-012243 | EDGAR | — |
| 2025-12-16 | 0001193125-25-320150 | EDGAR | — |
| 2025-12-10 | 0001193125-25-314165 | EDGAR | — |
| 2025-11-20 | 0001193125-25-288770 | EDGAR | — |
| 2025-11-17 | 0001193125-25-283893 | EDGAR | — |
| 2025-10-30 | 0001193125-25-257347 | EDGAR | — |
| 2025-09-22 | 0001193125-25-209934 | EDGAR | — |
| 2025-08-07 | 0000950170-25-104531 | EDGAR | — |
89 total filings indexed. 62 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001861560 |
| Ticker | NUVL |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.nuvalent.com |
| Listed | 2021-07-29 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/NUVL (~200 tokens, structured JSON with cryptographic provenance)